Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomibtreated patients: A report from retrospective study

Japanese Journal of Clinical Oncology

Volumn 41, Issue 7, 2011, Pages 876-881

  Aoki, Tomohiro ^a   Nishiyama, Takahiro ^a   Imahashi, Nobuhiko ^a   Kitamura, Kunio ^a  

^a Ichinomiya Municipal Hospital   (Japan)

Author keywords

Acyclovir; Bortezomib; Herpes zoster; Multiple myeloma; Prophylaxis

Indexed keywords

ACICLOVIR; BORTEZOMIB; DEXAMETHASONE;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG USE; FEMALE; GENDER; HERPES ZOSTER; HUMAN; INFECTION RISK; LOW DRUG DOSE; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; RELAPSE; RETROSPECTIVE STUDY; VIRUS REACTIVATION;

ACYCLOVIR; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; BORONIC ACIDS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 79960048540     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr063     Document Type: Article

References (23)

1. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 004;127:165-72.
2. Richardson PS, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
3. Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008;26:4784-90.
4. Kroger N, Zabelina T, Ayuk F, Atanackovic D, Schieder H, Renges H, et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 2006;34:770-5.
5. Tong Y, Qian J, Li Y, Meng H, Jin J. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. Am J Hematol 2007;82:403-4.
6. Wu KL, van Wieringen W, Vellenga E, Zweegman S, Lokhorst HM, Sonneveld P. Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice. Haematologica 2005;90:996-7.
7. Hambleton S, Gershon AA. Preventing varicella-zoster disease. Clin Microbiol Rev 2005;18:70-80.
8. Blanco B, Perez-Simon JA, Sanchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006;107:3575-83.
9. Kanaan N, Luo H, Wu J. Proteasome activity is required for T lymphocyte aggregation after mitogen activation. J Cell Biochem 2001;81:347-56.
10. Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006;108:2165-72.
11. Pour L, Adam Z, Buresova L, Krejci M, Krivanova A, Sandecka V, et al. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma 2009;9:151-3.
12. Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 2009;115:229-32.
13. Kim SJ, Kim K, Do YR, Bae SH, Yang DH, Lee JJ. Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. Jpn J Clin Oncol 2011;41:353-7.
14. Hasegawa Y, Kawahara F, Nagai H, Hirose T, Imai Y, Ishiguro T, et al. Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy. Rinsho Ketsueki 2009;50:488-94.
15. Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H, et al. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2008;83:472-6.
16. Feller L, Jadwat Y, Bouckaert M. Herpes zoster post-herpetic neuralgia. SAD J 2005;60:6-7.
17. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995;155:1605-9.
18. Gilden DH, Cohrs RJ, Mahalingam R. Clinical and molecular pathogenesis of varicella virus infection. Viral Immunol 2003;16:243-58.
19. Heider U, Rademacher J, Kaiser M, Kleeberg L, von Metzler I, Sezer O. Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma Leuk 2010;10:134-7.
20. Dasanu CA, Alexandrescu DT. Prophylactic antivirals may be helpful in prevention of varicella-zoster virus reactivation in myeloma, but are they safe? J Oncol Pharm Pract 2010;16:266-8.
21. Kanda Y, Mineishi S, Saito T, Saito A, Yamada S, Ohnishi M, et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;28:689-92.
22. Kim DH, Messner H, Minden M, Gupta V, Kuruvilla J, Wright J, et al. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis 2008;10:90-8.
23. Thomson KJ, Hart DP, Banerjee L, Ward KN, Peggs KS, Mackinnon S. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005;35:1065-9.